Scan the QR code to access an electronic copy of the poster (‘smart poster’) that includes links to the audio poster summaries from these co-authors DIA 2020 Global Annual Meeting; #89465 What pharmaceutical company leaders say and what patient leaders think: Quantitative and qualitative analyses Introduction • Pharmaceutical company leaders (eg, board chairs) can help drive a patient-focused cultural shift in their organizations. • Cultural change could be signalled through the words used by board chairs in their widely circulated, highly visible, and influential annual reports. • This ‘top down’ signalling could reinforce a company-wide commitment to partnering with patients, as well as reflecting ‘bottom up’ patient-centric initiatives being pursued across the company. Objectives To investigate: A. The frequency and context of the use of the word ‘patient’ by board chairs of the top 10 global pharmaceutical companies, and whether this usage changed from 2008–2018 B. How usage related to patient groups’ views of these companies. References 1. INVOLVE UK. What is public involvement in research? Available from: https://www.invo.org.uk/find-out-more/what-is-public-involvement-in-research-2/ 2. Corporate reputation of pharma in 2018 - the patient perspective (publicly accessible information only). Available from: https://www.lundbeck.com/upload/global/files/pdf/features/PATIENTVIEW%20PRESS%20RELEASE%2 0APRIL%202018.pdf Acknowledgments and disclosures We thank Envision Pharma Group for funding poster development. KW, LA, AB are Envision employees. CS was paid by Envision to prepare the audio script; no payment was received for authorship. All authors support patient involvement in medicines development. Results A. Frequency and context of the use of the word ‘patient’ by board chairs in annual reports Karen L. Woolley,aCarole Scrafton,b Amanda Boughey,cLauri Arnsteinc aEnvision Pharma Group, Australia, and University of Queensland, Australia; University of the Sunshine Coast, Australia; bFibroFlutters, UK; cEnvision Pharma Group, UK Methods 1 Obtain e-copies of the 2008 and 2018 annual reports of the top 10 global pharmaceutical companies (based on 2018 sales). 2 Use summative content analysis to assess the frequency and context of use (based on definitions adapted from INVOLVE UK1). 3 Compare results to PatientView rankings of these companies based on input from 1500 patient groups in 78 countries.2 0.44% 0.69% 2008 2018 • Use of the word ‘patient’ was low (<1% of words used) • Use remained low, but increased in 2018 Mean word count of annual report = 1627 Mean use of ‘patient’ = 7.5 (0–21) Mean word count of annual report = 1390 Mean use of ‘patient’ = 10.1 (0–45) B. Comparison with PatientView rankings 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 Pfizer Roche Novartis J&J Merck & Co (MSD) Sanofi AbbVie GSK Amgen Gilead % of annual report word count 2008 2018 • Use of ‘patient’ as an active partner was low (<5% of use)* • Use as an active partner remained low, but increased in 2018 1.86% 3.87% 2008 2018 We listen intently to healthcare communities, starting with patients, who visit our facilities to speak with, teach, and inspire us. Robert A. Bradway, Board Chair, Amgen, 2018 Example of active partner use““ * For reporting integrity and completeness, board chairs would need to review robust metrics on ‘patients as active partners’ initiatives across their companies (eg, via a Patient Partnership Dashboard with metrics for active partnerships by region, by function, by therapeutic area). Words matter. Pharmaceutical company leaders could help drive a patient-focused culture by enhancing the frequency and context of their use of the word ‘patient’ in their annual reports ^can Limitations • Pharmaceutical companies could have had active partnership projects with patients that were not reflected in board chair reports. • Our sample only included the top 10 global pharmaceutical companies. • We could only use the publicly accessible ranking inf